One large electronic database study showed there was a significantly increased risk of diabetic macular edema following GLP-1RA initiation compared to sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Weight loss patches work by releasing ingredients through the skin (transdermally), much like a nicotine patch, to release ingredients directly into your bloodstream
doi:10.1056/nejmoa2502081 You must be logged in to post a comment.
Headache occurs in 6-8% of patients, while dizziness and fatigue are less common
Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available
Effective Jan
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
